AstraZeneca’s Strensiq Gains Approval for Rare Disease Therapy in Guangdong Under “Hong Kong-Macau Drug and Device Access”
LONDON—AstraZeneca (NASDAQ: AZN, LON: AZN) , a leading UK-based pharmaceutical company, has announced that its...
Greater Bay Area
CNBG and University of Macau Ink Deal to Establish Joint Biotech Lab
China National Biotec Group Company Ltd (CNBG) has announced a strategic collaboration with the University...
Luye Pharma Group Secures RMB 1.6 Billion Investment to Boost Financials and R&D
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced that...
Novartis’s Tabrecta Earns NMPA Nod for MET-Positive Advanced NSCLC in China
Swiss pharmaceutical titan Novartis has secured marketing approval from China’s National Medical Products Administration (NMPA)...
Hong Kong SAR and NMPA Renew Agreements to Boost Drug and Medical Device Regulation
Professor Chung-mau LO, BBS, JP, Secretary for Health of the Hong Kong Special Administrative Region...
GBA Center of NMPA Launches Filing Guidance for Pharmaceutical Enterprises
The Guangdong-Hong Kong-Macau Greater Bay Area (GBA) Center for Drug Evaluation and Inspection, under the...
InnoCare Pharma Reports 2023 Revenue Growth and Pipeline Expansion
InnoCare Pharma (HKG: 9969; SHA: 688428), a Beijing-based biotech company, has released its financial report...
Fosun Health and Adventist Medical Center Partner to Enhance GBA Medical Services
China-based Fosun Health Consumption Industry Group has entered into a strategic partnership with Hong Kong’s...
China Unveils Action Plan to Boost Foreign Investment and Open Economy Further
The State Council of China has unveiled an ambitious “Action Plan to Promote the High-Level...
China Resources Guangdong Pharmaceutical Partners with BD to Enhance Drug and Device Distribution in GBA
China Resources Guangdong Pharmaceutical Co., Ltd has entered into a strategic partnership with U.S.-based Becton,...
Everest Medicines Stakeholders Pledge Six-Month Hold Amid Confidence in Long-Term Growth
Everest Medicines (HKG: 1952), a Chinese pharmaceutical firm, has received commitments from its controlling shareholder...
Everest Medicines’ Velsipity NDA Accepted in Macau, Poised for First Asian Approval
Everest Medicines (HKG: 1952), based in China, has announced that its New Drug Application (NDA)...
BMS’s Azacitidine, First Oral AML Therapy, Reaches GBA Patients via Special Policy
Bristol-Myers Squibb (BMS, NYSE: BMY), a leading US pharmaceutical company, has announced the clinical application...
Guangdong Province Releases New Batch of Urgently Needed Drugs and Medical Devices for Greater Bay Area
The Medical Products Administration and Health Commission of Guangdong province have released the sixth batch...
InnoCare Makes Minjuvi Combo Treatment Available to Patients in China’s GBA
InnoCare (HKG: 9969; SHA: 688428), a China-based biopharmaceutical company, has announced that the combination treatment...
Guangdong Aims to Boost Biomedicine Industry with Incentives and Strategic Development
The Guangdong Provincial Development and Reform Commission has unveiled an ambitious set of measures aimed...
China’s State Council Unveils 26 Initiatives to Enhance Grey-hair Economy
The State Council has unveiled the “Opinions on Developing the Grey-hair Economy to Boost Wellbeing...
Hong Kong Aims for “First-Level Approvals” with New Drug Regulatory Institution
Hong Kong is taking steps to establish a drug regulatory institution that will permit “first-level...
Luye Pharma’s Lurbinectedin Receives Market Approval in Hong Kong for SCLC Treatment
China-based Luye Pharma Group (HKG: 2186) has announced that Hong Kong’s pharmacy and poisons board...
Haplox and Illumina Mark Milestone with Production of NextSeq 2000Dx-CN-HAP Sequencing System in China
Haplox Biotechnology Co., Ltd, a Chinese biotech firm, and US industry leader Illumina (NASDAQ: ILMN)...